Cargando…

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

Detalles Bibliográficos
Autores principales:	Grimaldi, Antonio Maria, Simeone, Ester, Festino, Lucia, Giannarelli, Diana, Palla, Marco, Caracò, Corrado, Curvietto, Marcello, Esposito, Assunta, Grimaldi, Maria Chiara, Mozzillo, Nicola, Ascierto, Paolo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649387/ http://dx.doi.org/10.1186/2051-1426-3-S2-P186

Ejemplares similares

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis
por: Di Monta, Gianluca, et al.
Publicado: (2017)

High expression of a spliced variant of FKBP51 in peripheral blood mononuclear cells of melanoma patients may be related to PDL-1 on tumour and predictive of response to Ipilimumab
por: Simeone, Ester, et al.
Publicado: (2014)

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
por: Simeone, Ester, et al.
Publicado: (2019)

Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis
por: Caracò, Corrado, et al.
Publicado: (2013)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters
por: Simeone, Ester, et al.
Publicado: (2014)

Ipilimumab and Stereotactic Radiosurgery with CyberKnife(®) System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience
por: Borzillo, Valentina, et al.
Publicado: (2021)

The role of spectrophotometry in the diagnosis of melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2010)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2014)

Clinicopathologic features and surgical management of primary umbilical melanoma: a case series
por: Di Monta, Gianluca, et al.
Publicado: (2015)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
por: Mozzillo, Nicola, et al.
Publicado: (2012)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2006)

Resection in the popliteal fossa for metastatic melanoma
por: Marone, Ugo, et al.
Publicado: (2007)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors
por: Mozzillo, Nicola, et al.
Publicado: (2013)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2013)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Quality of Life Predictors in Patients With Melanoma: A Machine Learning Approach
por: Pinto, Monica, et al.
Publicado: (2022)

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
por: Ascierto, Paolo A, et al.
Publicado: (2010)

Epigenetic Regulation in Melanoma: Facts and Hopes
por: Giunta, Emilio Francesco, et al.
Publicado: (2021)

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification
por: Hotson, Drew, et al.
Publicado: (2014)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series
por: Carlino, Matteo S, et al.
Publicado: (2016)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tr6eop35f9u3gts5lddcc9i54u